Photodynamic therapy (PDT) is a cytotoxic treatment using singlet oxygen produced by photosensitizers. Approved porphyrinoid PDT still suffers from a lack of robust production methods and low water solubility. Methylene blue (MB) is a good candidate for the PDT drug, because the dye is an effective photosensitizer, can be easily synthesized, and is already being used in other clinical fields. However, its poor cell/tissue penetration and low stability against the reducible biological conditions should be addressed by using a proper delivery vehicle. Here, we employed a DNA tetrahedron, a self-assembled nanostructure as the carrier for intracellular delivery of MB by taking advantage of the DNA binding property of the photosensitizer and demonstrated photo-induced cytotoxicity by the MB delivered by the DNA nanocarrier. We also evaluated the PDT potency of the MB-loaded DNA nanoconstruct in vivo tumor model to suppress tumor growth.
Bibliographical noteFunding Information:
This study was supported by the intramural programs of KIST, the Global Innovative Research Center program (2012K1A1A2A01055811) of the National Research Foundation of Korea and by the Intramural Research Programs (Global RNAi Carrier Initiative and Convergence Technology Program) of KIST, the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (2014-R1A2A2A04002526), and a grant by the Pioneer Research Center Program through NRF funded by the Ministry of Science, ICT and Future Planning (2014M3C1A3054141).
© 2016 The Royal Society of Chemistry.
All Science Journal Classification (ASJC) codes
- Biomedical Engineering
- Materials Science(all)